within Pharmacolibrary.Drugs.ATC.L;

model L03AB08
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00055,
    adminDuration  = 600,
    adminMass      = 0.25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00025,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00023999999999999998,
    k12             = 28,
    k21             = 28
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L03AB08</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Interferon beta-1b is a recombinant form of human interferon beta used as an immunomodulatory agent in the treatment of relapsing forms of multiple sclerosis (MS). It functions by modifying the immune response and reducing inflammation. Interferon beta-1b is an FDA- and EMA-approved medication that has been in clinical use for MS for several decades.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters following subcutaneous administration of 250 micrograms in healthy adult volunteers.</p><h4>References</h4><ol><li><p>Khan, OA, et al., &amp; Dhib-Jalbut, SS (1996). Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration. <i>Neurology</i> 46(6) 1639–1643. DOI:<a href=&quot;https://doi.org/10.1212/wnl.46.6.1639&quot;>10.1212/wnl.46.6.1639</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8649563/&quot;>https://pubmed.ncbi.nlm.nih.gov/8649563</a></p></li><li><p>Buttmann, M, &amp; Rieckmann, P (2007). Interferon-beta1b in multiple sclerosis. <i>Expert review of neurotherapeutics</i> 7(3) 227–239. DOI:<a href=&quot;https://doi.org/10.1586/14737175.7.3.227&quot;>10.1586/14737175.7.3.227</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17341170/&quot;>https://pubmed.ncbi.nlm.nih.gov/17341170</a></p></li><li><p>Chiang, J, et al., &amp; Williams, GJ (1993). Pharmacokinetics of recombinant human interferon-beta ser in healthy volunteers and its effect on serum neopterin. <i>Pharmaceutical research</i> 10(4) 567–572. DOI:<a href=&quot;https://doi.org/10.1023/a:1018902120023&quot;>10.1023/a:1018902120023</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/8483840/&quot;>https://pubmed.ncbi.nlm.nih.gov/8483840</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L03AB08;
